Royce & Associates LP lowered its position in CeriBell, Inc. (NASDAQ:CBLL – Free Report) by 7.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 559,544 shares of the company’s stock after selling 45,466 shares during the period. Royce & Associates LP owned approximately 1.44% of CeriBell worth $13,647,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also added to or reduced their stakes in CBLL. Lisanti Capital Growth LLC purchased a new stake in shares of CeriBell in the third quarter worth approximately $4,466,000. Squarepoint Ops LLC bought a new stake in shares of CeriBell during the 2nd quarter worth approximately $638,000. Wellington Management Group LLP boosted its holdings in CeriBell by 5.5% during the 2nd quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock valued at $1,706,000 after acquiring an additional 4,572 shares during the period. Formula Growth Ltd. purchased a new position in CeriBell during the 2nd quarter valued at $603,000. Finally, Bank of America Corp DE bought a new position in CeriBell in the 2nd quarter valued at $4,619,000.
Wall Street Analyst Weigh In
A number of research firms have weighed in on CBLL. TD Cowen increased their target price on CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. BTIG Research reissued a “buy” rating on shares of CeriBell in a research note on Wednesday, November 4th. Canaccord Genuity Group upped their price target on shares of CeriBell from $26.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Finally, Barclays upgraded CeriBell to a “neutral” rating in a report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $31.25.
Check Out Our Latest Stock Report on CBLL
Insider Buying and Selling at CeriBell
In other news, CFO Scott Blumberg sold 33,512 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $25.03, for a total value of $838,805.36. Following the completion of the sale, the chief financial officer owned 148,121 shares in the company, valued at approximately $3,707,468.63. The trade was a 18.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Joseph Taylor sold 10,200 shares of the company’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $27.22, for a total transaction of $277,644.00. Following the completion of the sale, the director directly owned 38,278 shares of the company’s stock, valued at $1,041,927.16. The trade was a 21.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 191,708 shares of company stock worth $4,815,764. 17.70% of the stock is currently owned by company insiders.
CeriBell Stock Performance
Shares of CeriBell stock opened at $26.42 on Tuesday. The company has a current ratio of 8.18, a quick ratio of 7.79 and a debt-to-equity ratio of 0.17. The stock’s fifty day moving average price is $25.56 and its 200-day moving average price is $21.07. The firm has a market cap of $1.03 billion, a P/E ratio of -13.62 and a beta of 0.86. CeriBell, Inc. has a 12 month low of $12.65 and a 12 month high of $28.89.
CeriBell (NASDAQ:CBLL – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. The business had revenue of $29.34 million during the quarter, compared to analysts’ expectations of $29.18 million. On average, equities research analysts expect that CeriBell, Inc. will post -2.05 earnings per share for the current fiscal year.
About CeriBell
Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.
Further Reading
- Five stocks we like better than CeriBell
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
